New, oral treatment option for rheumatoid arthritis
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
An oral treatment option, the combination of methotrexate and the chemically synthesised Janus Kinase Inhibitor tofacitinib, has found to be equally effective as the current combination of methotrexate/adalimumab. The latter has to be injected into patients every two weeks while new option involves taking two tablets a day. Tofacitinib inhibits particular enzymes, which are jointly responsible for the inflammatory response in rheumatoid arthritis. JAKs carry signals from various inflammatory messenger substances, such as interleukin-6 or interferons, into the cell and are therefore largely responsible for triggering the destructive inflammation that occurs in rheumatoid arthritis. If these enzymes are inhibited, the painful immune response that occurs in this autoimmune disease is suppressed...


http://bit.ly/2suZFJJ
Dr. T●●●j S●●●●●i and 8 others like this
Like
Comment
Share